Oliceridine / Sufentanil / Obstructive Sleep Apnea · Observational Study

Oliceridine Versus Sufentanil Analgesia for Postoperative Patients With Obstructive Sleep Apnea

ClinicalTrials.gov · August 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a prospective observational study registry record comparing oliceridine and sufentanil for postoperative analgesia in patients with obstructive sleep apnea, with respiratory depression incidence as the primary outcome. No results have been posted; the study has not yet begun recruitment. The mechanistic rationale for oliceridine's potential respiratory advantage is stated, but clinical evidence is pending.

What was studied

Observational. Obstructive Sleep Apnea, Postoperative Analgesia, Oliceridine, Sufentanil, Respiratory Depression; age from 18 Years; to 90 Years. Intervention: Oliceridine cohort; Sufentanil cohort. Compared with: Sufentanil (conventional opioid).. n = 851. 1 site: China.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registry record for a planned observational study with no results posted; enrollment is not yet begun, making it a prospective design description only.

Study design

As stated by the source record.

MethodsCohort model. Prospective time perspective. Primary outcome measure: Incidence of respiratory depression within 24 hours after surgery (assessed at Within 24 hours after surgery)

DesignObservational

PopulationObstructive Sleep Apnea, Postoperative Analgesia, Oliceridine, Sufentanil, Respiratory Depression; age from 18 Years; to 90 Years

Sample size851

InterventionOliceridine cohort; Sufentanil cohort

ComparatorSufentanil (conventional opioid).

Setting1 site: China

Reported figures

Quoted from the source exactly as published.

Planned enrollment851

Primary outcome measureIncidence of respiratory depression within 24 hours after surgery

Caveats

This is a registry record; no results are reported or available.
Observational design limits causal inference and control of confounding variables.
Recruitment has not begun (NOT_YET_RECRUITING status).
No secondary outcomes, statistical analysis plan, or follow-up duration beyond 24 hours are stated in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Observational design without randomization or blinding; no control of confounding.

Directness

strong

Primary outcome is clinically hard: respiratory depression incidence within 24 hours postoperatively.

Consistency

insufficient

No results reported; consistency cannot be assessed from a registry record.

Risk of bias

limited

Observational design vulnerable to selection and confounding bias; no blinding stated.

Sample adequacy

moderate

Planned enrollment 851 participants; adequate size for primary outcome but not yet recruited.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07753785). This is a study registration, not published results. Lead sponsor: Peking University First Hospital. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 851 participants (ESTIMATED). Conditions: Obstructive Sleep Apnea, Postoperative Analgesia, Oliceridine, Sufentanil, Respiratory Depression. Interventions: DRUG: Oliceridine; DRUG: Sufentanil. Primary outcome measures: Incidence of respiratory depression within 24 hours after surgery , Within 24 hours after surgery. Brief summary: Opioids are frequently used for postoperative analgesia but may induce side effects. Opioid-induced respiratory depression is the most dangerous side effect of opioids. Patients with obstructive sleep apnea (OSA) are at higher risk for opioid-induced respiratory depression. Oliceridine is a novel biased μ-opioid receptor agonist that selectively engages the G-protein pathway while reducing β-arrestin recruitment and thus may lower the risk of respiratory depression. The goal of this observational study is to compare the effects of oliceridine versus sufentanil analgesia on the incidence of postoperative respiratory depression in patients with known or suspected OSA in the postoperative period following elective surgery.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

OliceridineSufentanilObstructive Sleep ApneaPostoperative AnalgesiaPeking University First HospitalNCT07753785Oliceridine